Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study-Reference-Cited by-同舟云学术

Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study

Published:2015-09-10 Issue:11 Volume:126 Page:1392-1394
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Kastritis Efstathios¹,Gavriatopoulou Maria¹,Kyrtsonis Marie-Christine²,Roussou Maria¹,Hadjiharissi Evdoxia³,Symeonidis Argyris⁴,Repoussis Panagiotis⁵,Michalis Evridiki⁶,Delimpasi Sosana⁷,Tsatalas Konstantinos⁸,Tsirigotis Panagiotis⁹,Vassou Amalia¹⁰,Vervessou Elina¹¹,Katodritou Eirini³,Gika Dimitra¹,Terpos Evangelos¹,Dimopoulos Meletios A.¹

Affiliation:

1. Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece

2. First Department of of Propaedeutic Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece

3. Theageneion Cancer Center, Thessaloniki, Greece

4. Department of Hematology, University of Patras School of Medicine, Patras, Greece

5. Metaxa Cancer Center, Piraeus, Greece

6. Department of Hematology, G. Genimatas Hospital, Athens, Greece

7. Department of Hematology and Bone Marrow Transplant, Evangelismos Hospital, Athens, Greece

8. School of Medicine, Democritus University of Thrace, Alexandroupolis, Greece

9. Second Department of Internal Medicine, National and Kapodistrian University of Athens, Haidari, Greece

10. Department of Hematology, University of Ioannina School of Medicine, Ioannina, Greece

11. Henry Dunant Hospital, Athens, Greece

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/126/11/1392/1388082/1392.pdf

Reference10 articles.

1. Clinicopathological definition of Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia.;Owen;Semin Oncol,2003

2. Prognostic markers and criteria to initiate therapy in Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia.;Kyle;Semin Oncol,2003

3. Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide.;Dimopoulos;J Clin Oncol,2007

4. Uniform response criteria in Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia.;Weber;Semin Oncol,2003

5. Clinical value of minor responses after 4 doses of rituximab in Waldenström macroglobulinaemia: a follow-up of the Eastern Cooperative Oncology Group E3A98 trial.;Gertz;Br J Haematol,2009

Cited by 110 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current Management of Waldenstrom Macroglobulinemia;Clinical Lymphoma Myeloma and Leukemia;2024-09

2. PembroWM: A phase II trial to investigate the safety and efficacy of rituximab and pembrolizumab in relapsed/refractory Waldenström's Macroglobulinaemia;British Journal of Haematology;2024-08-19

3. Simplified Risk Stratification Model for Patients With Waldenström Macroglobulinemia;Journal of Clinical Oncology;2024-07-20

4. Effectiveness, safety, and tolerability of delayed dexamethasone, rituximab, and cyclophosphamide as first-line treatment in patients with Waldenström macroglobulinemia: data from the Sicilian Myeloma Network;Frontiers in Hematology;2024-06-20

5. How to manage waldenström’s macroglobulinemia in 2024;Cancer Treatment Reviews;2024-04